ArticleAnnals of laboratory medicine2025
Optimized Protocol for Producing Pathogen-inactivated Double-dose Platelet Concentrates From Six Pooled Buffy Coats.
Article in Annals of laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimized pathogen reduction of double-dose platelets pooled from seven buffy coats using the TACSI® system.Vox sanguinis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pooled platelet (PLT) production methods differ worldwide. In Europe, the buffy coat (BC) method is predominantly used, with four to eight BCs being pooled to produce single- or double-dose PLT products. The European Directorate for the Quality of Medicines & HealthCare (EDQM) blood guide and Austrian legislation define a therapeutic PLT unit as ≥ 2 × 10 Methods: We stepwise optimized our protocol starting from five BCs (BC5) (N=107). First, we included an additional BC (BC6) (N=110). Second, we used a hematology analyzer (Sysmex XN-1000) equipped with blood bank mode, which is a novel software application for measuring PLT counts in PLT units (BC6+XN-1000) (N=106). Third, we optimized the blood cell separator (BCS) settings to produce higher-volume BCs (BC6+XN-1000+BCS) (N=107). Fourth, we adapted the centrifugation (BC6+XN-1000+BCS+CF) (N=197). All units were pathogen-inactivated using the INTERCEPT blood system (amotosalen/ultraviolet A). Results: Each optimization step significantly increased the yield ( × 10 Conclusions: After stepwise protocol optimization, we could produce pathogen-inactivated double-dose PLT concentrates by pooling six BCs, complying with national regulations and EDQM quality requirements while reducing costs and minimizing blood wastage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.